Stem cell 'secretome' may reboot the brain after stroke — a trial puts it to the test

NCT ID NCT07731087

Recruiting now Disease control Sponsor: Jumraini Tammasse Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This pilot trial tests whether a substance made from stem cells — called mesenchymal stem cell secretome — can improve cognitive recovery in people who have had an ischemic stroke. Participants aged 40 to 75 with mild-to-moderate cognitive impairment will receive either standard stroke care alone or standard care plus two doses of the secretome. The study measures changes in thinking skills, brain wave patterns, and blood markers of brain health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: umbilical cord mesenchymal stem cell-derived secretome
What this could lead to: If it works, this could point toward a new add-on treatment to improve thinking and memory after a stroke.
What could go wrong: This is a small early pilot trial, so results may not be conclusive. The therapy carries risks of allergic reactions or fever, and its benefits for cognition are unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC STROKE POST-STROKE COGNITIVE IMPAIRMENT

Contacts and locations

Locations

Hasanuddin University Hospital
RECRUITING

Makassar, South Sulawesi, 90245, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.